Lefamulin

来法莫林

Report date: 2026/05/26 20:00:28
NMEQIDP

Base Information

Drug NameLefamulin
Drug Alias Name拉法姆林注射液Lefamulin拉法姆林Xenleta信乐妥 +[8] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of Action50S ribosomal subunit modulators
Targets50S ribosomal subunit
Therapy Area/IndicationsCommunity Acquired PneumoniaCystic FibrosisPneumonia +[7] 
Global Approved IndicationsCommunity Acquired PneumoniaPneumoniaCommunity-Acquired Infections +[5] 
Approved Indications in ChinaInfections
Original Approved Country/TerritoryUnited States
Original Approved Date2019/08/19
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNabriva Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesHong Kong King-Friend Industry Co LtdRoivant Sciences IncNabriva Therapeutics Ireland Designated Activity Company +[6] 
Inactive CompaniesShanghai Lunsheng Pharmaceutical Technology Co Ltd
Active IndicationsCommunity Acquired PneumoniaCystic FibrosisPneumonia +[6] 
Inactive IndicationsBacterial Infections

Other Information

ATC CodeJ01XX12
Related LinksWikipediaDrugBankKEGG